We’re delighted to announce a Research Partnership study into the burden of illness in newly diagnosed Multiple Myeloma patients & their caregivers has been selected by the European Hematology Association for an e-poster presentation at the EHA 2021 Virtual Congress in June 2021. The poster, which is entitled, ‘The burden of a multiple myeloma diagnosis on patients and carers in the first year: Western European findings’ is authored by Market Access Director Brett Gardiner, Research Director Jenny Redfearn and Associate Director Victoria Spain in partnership with Janssen Pharmaceuticals.
About our poster
The burden of a multiple myeloma diagnosis on patients and carers in the first year: Western European findings
Multiple myeloma is the second most common haematological malignancy after leukaemia. Globally, its incidence increased by 126% between 1990 and 2016, and was the cause of 2.1 million disability adjusted life-year in 2016. Western Europe remains amongst the world regions with the highest age-standardised incidence rate. Despite the increasing evidence that substantiates the considerable burden of newly diagnosed multiple myeloma, it remains unclear how various aspects of the disease interrelate to the impact on the health and economic outcomes of patients and carers, particularly in the first year after diagnosis.
To quantify the burden of illness, newly diagnosed multiple myeloma patients and their carers in 4 EU countries (France, Germany, Italy, Spain) were recruited to take part in a longitudinal observational study between January 2019 and January 2021.
If you would like to learn more about the poster, please contact Brett Gardiner: firstname.lastname@example.org
Brett is a Director and heads up our specialist market access team. Brett has managed and contributed to the development of pricing and reimbursement strategies for pharmaceuticals and medical devices in all stages of the product life-cycle across all major European markets, US, Japan, Canada as well as many emerging markets. Brett has particular experience in asset valuation and value communication as well as more complex pricing research: moderation of payer and KOL dyads, focus groups, advisory boards, mock formulary committees and P&R negotiation simulations.